An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Zymeworks Inc. (NYSE: ZYME) will report its third quarter 2022 financial results on November 8, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. ET, providing insights into financial results and corporate updates. The company specializes in developing multifunctional biotherapeutics, with its lead candidate, zanidatamab, in various clinical trials targeting HER2 in solid tumors. Zymeworks is advancing other candidates including ZW49, a bispecific HER2-targeted antibody-drug conjugate currently in Phase 1.
Positive
Zymeworks is advancing multiple clinical candidates, including zanidatamab in pivotal trials and ZW49 in Phase 1.
The company is actively leveraging strategic partnerships to enhance its therapeutic platforms.
Negative
None.
VANCOUVER, British Columbia--(BUSINESS WIRE)--
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its third quarter 2022 financial results after market close on November 8th, 2022. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on November 8th, 2022 at 4:30 p.m. ET.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2 ‑targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit www.zymeworksclinicaltrials.com. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.
